Oncology Market Access at Risk: Is a Carrot for MDs a Stick for Pharma Companies
When Considering a Merger, Ask Why
Building the Fundamentals: Why Bold Sales Incentive Schemes Need Efficient Administration
Why Medtech's Commercial Models Must Adapt to Local Needs
Allergan Case Study: A Smart Response to Growth
Biopharma Companies Identify Biggest Challenges and Opportunities in Targeting and Activity Planning
Jon Roffman and Anand Vishwarupe co-wrote this blog post with Sankalp Sethi.
Oncology manufacturers spend more than $4 billion on supporting their sales forces and promoting their therapies to physicians, according to ZS analysis, but with the decision-making process moving away from individual physicians, are manufacturers wasting their efforts?
Read MoreTopics: customer engagement, sales force effectiveness, oncology, HCP, physician, oncology manufacturer, prescribing behaviors, treatment decisions, go-to-market model, localization, provider control
Jon Roffman and Anand Vishwarupe co-wrote this blog post with Sankalp Sethi.
Oncology manufacturers spend more than $4 billion on supporting their sales forces and promoting their therapies to physicians, according to ZS analysis, but with the decision-making process moving away from individual physicians, are manufacturers wasting their efforts?
View All ZS Offices
